Sudesh Kamath
Senior Director, Head of Regulatory Affairs CMC at QED Therapeutics - Palo Alto, CA, US
Sudesh Kamath's Colleagues at QED Therapeutics
Sudesh Kamath's Contact Details
HQ
650-231-4088
650-231-4088
Location
San Francisco,California,United States
San Francisco,California,United States
Company
QED Therapeutics
QED Therapeutics
Sudesh Kamath's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Sudesh Kamath
Sudesh Kamath currently works for QED Therapeutics.
Sudesh Kamath's role at QED Therapeutics is Senior Director, Head of Regulatory Affairs CMC.
Sudesh Kamath's email address is ***@qedtx.com. To view Sudesh Kamath's full email address, please signup to ConnectPlex.
Sudesh Kamath works in the Research industry.
Sudesh Kamath's colleagues at QED Therapeutics are Mag Sellakumaran, Kathleen Dm, Jack Winnike, Anne Lee, Keith Steward, Roo Vold, Joyce Velez and others.
Sudesh Kamath's phone number is 650-231-4088